External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
about
Contemporary Treatment of Metastatic Renal Cell CarcinomaCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewCytoreductive nephrectomy and its role in the present-day period of targeted therapy.Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementPredictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinomaMedical treatment of renal cancer: new horizonsImmunotherapy for metastatic renal cell carcinoma.Renal cell carcinoma.Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsPrognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyTetravalent antibody-scTRAIL fusion proteins with improved properties.Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma.First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma.Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case seriesDNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyNivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinomaA retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapyBody Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysisApplication of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma.
P2860
Q26740594-5F9E3E5D-FFC4-42CC-87B6-E3BE4D1ABE3AQ26774515-8D71B0B9-2E1F-4E8D-BB1B-E2EDBD6C0943Q26783520-0D018818-912C-4D8B-8BF0-9BF6668A3D6CQ26801279-57B25433-7EAE-45DB-811E-85168B83648AQ28067482-269AAB25-C989-422D-BA81-266508128846Q28073174-CC593BF1-6C17-4156-8542-213861AF4487Q30234458-C9F54848-33F3-497D-A602-F0187D06D77CQ30235364-60163640-B176-4FC2-B1DA-E9048A06FDF4Q30487077-B5CD9BCA-119F-495D-8954-DF2A56DB45E4Q33417828-DACBE839-43EA-4D83-8244-2F21221BA4A1Q33423740-6C4F96F7-719C-46C6-A155-01E47C40F3DAQ33426559-19AE316D-B0ED-432C-AD27-C601E6C16C67Q33426958-728DBBD0-511C-4810-AED4-D7CED92F6D62Q33431578-DDC1CEBD-059D-46E5-A36D-179FBC7923E7Q33439523-506994C7-F987-4AA1-B7C5-47B81EEF251CQ33577856-5892A1D4-9203-4940-A535-06E41790B4A7Q33619046-39403A39-BDA4-435A-80D8-246CC28562BCQ33648983-849B0071-104C-488C-B500-CECDF2BE5A10Q33684941-8EABD9C7-F8FB-4621-AF9F-6A01E3B7D49DQ33696649-A97D1242-75A3-457B-B3CC-00CB40606BB6Q33814322-6977A88C-47C5-47B1-AD10-24A5170E870CQ34138032-51F0E095-B120-472C-A513-5B9106B028F5Q34351372-ECD0CE6C-5F89-41E9-AF44-B94F14400A29Q34354554-980389D0-96DF-49F5-AAE7-80791CDC2A6EQ35068826-CF025CD3-90D3-4D4D-ACDD-8ED6F375468EQ35122019-01EC8F28-6628-45A8-8073-829C8C8BD22FQ35274936-2B8E91A7-E71F-4ADA-AD8B-F1BBD2CFE442Q35674216-65B0A331-4954-4AD1-A0A8-94C036F6A8DFQ35741056-3D23BBD3-6CEC-449F-8CC1-B29B8B327984Q35802508-E5E2739A-D786-4ADE-8FAA-C18030489370Q35832449-85AC2848-D9A0-4F57-B1CF-9C6F0F3F1F80Q35918881-6EE02F6E-F08A-44F8-BC8E-D4C1DED6A70CQ36043473-23700F02-E5F0-4644-94E9-2D9AFF767A58Q36074171-1E31DBEA-B077-4CB2-8619-9C7E56203056Q36092829-ED352B60-F22E-4B2F-91F4-DBE13E04BAB2Q36124825-ADCEEF12-99ED-4A68-B956-31E5F377273CQ36132720-394F8768-E9CD-4DDA-947C-CC74FCFC8DC8Q36384503-263DBF27-02D3-42B1-8A7B-A4D3FAFF000CQ36443895-102CD896-551F-49C3-82F1-273E5B2D71D9Q36855805-392B0E51-D2A1-4741-9797-C87CF234430B
P2860
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
External validation and compar ...... odel: a population-based study
@ast
External validation and compar ...... odel: a population-based study
@en
External validation and compar ...... odel: a population-based study
@nl
type
label
External validation and compar ...... odel: a population-based study
@ast
External validation and compar ...... odel: a population-based study
@en
External validation and compar ...... odel: a population-based study
@nl
prefLabel
External validation and compar ...... odel: a population-based study
@ast
External validation and compar ...... odel: a population-based study
@en
External validation and compar ...... odel: a population-based study
@nl
P2093
P2860
P50
P1433
P1476
External validation and compar ...... odel: a population-based study
@en
P2093
Brian I Rini
Christian Kollmannsberger
Daniel Y C Heng
Lauren C Harshman
Mary Mackenzie
Meredith M Regan
Min-Han Tan
Neeraj Agarwal
Toni K Choueiri
P2860
P304
P356
10.1016/S1470-2045(12)70559-4
P577
2013-01-09T00:00:00Z